Stay updated on Margetuximab in Advanced Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Margetuximab in Advanced Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Margetuximab in Advanced Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:55:47.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update or revision in the study details related to the effectiveness of the anti-HER2 monoclonal antibody, MGAH22, in patients with relapsed or refractory advanced breast cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:06.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying the health conditions and prior treatments required for inclusion. Previously, no information was provided under the 'Participation Criteria' section.
    Difference
    31%
    Check dated 2024-05-22T21:33:12.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:22:12.000Z thumbnail image

Stay in the know with updates to Margetuximab in Advanced Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Margetuximab in Advanced Breast Cancer Clinical Trial page.